FILE:ABT/ABT-8K-20091130123646.txt.gz
EVENTS:	Other Events
TEXT:
ITEM: Other Events
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
o
   
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
Item 8.01  Other Events.
 
Abbott Laboratories and the patent owner, Laboratories Fournier S.A., have entered into a license agreement with Teva Pharmaceuticals USA Inc. granting Teva rights to intellectual property for Tricor 145 mg no sooner than March 28, 2011. Under certain defined circumstances, Teva may not receive rights to this intellectual property until July 1, 2012.
 
Some statements in this Form 8-K may be forward-looking statements for the purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors," to Abbott's Annual Report on Securities and Exchange Commission Form 10-K for the year ended December 31, 2008.  Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


